NCT05617755 - AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

February 28, 2027

Conditions

Carcinoma, Ovarian EpithelialOvarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsNeoplasms, Glandular and EpithelialOvarian DiseasesGenital Neoplasm, FemaleAbdominal NeoplasmRecurrence

Interventions

BIOLOGICAL

AB-1015

autologous T cell therapy

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

14203

Roswell Park Comprehensive Cancer Center, Buffalo

48201

Barbara Ann Karmanos Cancer Institute, Detroit

52242

U of Iowa Health Care, Iowa City

77030

MD Anderson Cancer Center, Houston

80045

U of Colorado Cancer Center - Anschutz Medical Campus, Aurora

94158

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

98195

U of Washington - Fred Hutchinson Cancer Center, Seattle